IN BRIEF: Federal Circuit won’t revisit Amgen’s win on blockbuster Enbrel patents – Reuters

IN BRIEF: Federal Circuit won’t revisit Amgen’s win on blockbuster Enbrel patents – Reuters

The U.S. Court of Appeals for the Federal Circuit on Tuesday declined further review of a panel decision that blocked Novartis AG’s Sandoz unit from offering a biosimilar of Amgen’s arthritis drug Enbrel (etanercept) until 2029.

Read More…

You May Also Like